lindas have a posse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Trillion dollar technology. I am buying Monday.
Sunseeker 75.
Big baller you are
I can't figure out what yacht to buy.
I am buying more Monday.
OMG. “ALL OPERABLE TUMORS”!!!!! Was just DM’d this. Have to assume it’s @ASCO today. $nwbo pls confirm. pic.twitter.com/nZTXPnaJM7
— annie post (@apwriter) June 3, 2023
Trodelvy was for a niche cancer cancer indication, triple negative breast cancer, while it's a monotherapy not a platform treatment. It also already has competition most notably from AstraZeneca and Daiichi Sankyo's Enhertu which showed great results at ASCO 2022. DCVax worth a lot more than Trodelvy.
It doesn't matter if ASCO endorses the presentation. We have an audience at ASCO.
We also already have JAMA.
Yes thats what the Google machine says.
It does. Thank you.
I saw that. I am not an expert in this regard. TLR-3 includes PolyICLC?
I didn't see PolyICLC in the patent.
Only buy a company you would feel great about holding for 5 years or more.
Our stock was trading above $1 not long ago. The manipulation will not endure.
NWBO can easily move ten cents on some new information regarding management's plan for all solid tumors. The title tomorrow happens to be solid tumors not Glioblastoma. That implies more trials for additional indications as SEC 10Q/K make clear are management priorities. It implies management do not forsee issues with global approval for Glioblastoma.
Popping bottles tomorrow for sure.
It was not easy to hold since early 2020 without any sell orders but I made it happen.
Novocure longs post DCVax approval.
Buy Now Or Cry Later!
You will see the SS Linda Powers parked in Cassis France very soon.
Equities are massively overvalued. The bond market says recession. Only a few companies like NWBO will be in a bull market once the recession hits. Demand for DCVax isn't determined by the unemployment rate.
NWBO are a 100 billion dollar company.
I am in the green. That isn't dead money. I can sell now if I want. Sorry if you bought at 2.50. Take your complaining elsewhere.
Trillion dollar technology.
I added 68K shares today now at 550K total in NWBO. Overweight, an understatement!
Excellent opening opportunity Monday post ASCO. I believe we will be above 0.75 after the Bosch presentation.
Glad to help.
Now at 550K shares.
Linda Liau has a board position at ClearPoint Neuro. I can see her taking a board seat at NWBO as part of a Merck partnership. That would be a natural synergy.
Buying NWBO isn't something one does on a whim.
If shareholders were unhappy they would be selling in large volume. The opposite true. Looks like my order will not fill today.
Trying 69K @ 0.5959.
I don't see any issues. Some simply like to complain.
Bourbon isn't the solution.
Q4 2023 in my opinion seems very realistic for UK approval. It could be sooner.
Adam Feuerstein needs to stop spreading lies.
Nothing has been delayed. There's no approval timeline benchmark against which to compare this personalized autologous cell-based therapy. So when you say X number of GBM patients died, while management are delayed, that isn't factual in any respect. They're not late, delayed, or dealing with some fatal issue that precludes approval.
You have no idea what's going on behind the scenes. From SEC filings and PRs we know that they're working on approval. If negative feedback was given by MHRA, FDA, et al, that would be a mandatory disclosure. In reality the opposite occurred at every step. The notion that management are responsible for the deaths of GBM patients to me seems like absolute lunacy as without their efforts this life-saving treatment wouldn't be, in my opinion, months away from approval.
JAMA, MHRA, FDA, Health Canada, EMA all love DCVax.
More GBM patients died taking Temodar than DCVax. So if you are upset at a management team it should be those who have the financial resources to address the problem. We have the technology and soon the money as well.
Wrong yet again
Hey bro welcome to Northwest Biotherapeutics IHUB forum.